Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02 2023 - 8:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage
biopharmaceutical company dedicated to the research, development
and commercialization of innovative therapies for rare and severe
diseases of the eye, today announced that it will present at the
Jefferies Healthcare Conference being held in New York, NY. Members
of Kala’s management team will participate in a fireside chat on
Friday, June 9, 2023 at 11:55 a.m. ET. Management will also be
available for one-on-one meetings on Friday, June 9, 2023.
To access the webcast and subsequent archived recording of the
fireside chat, please visit the “Presentations” section of the Kala
website at www.kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a clinical-stage biopharmaceutical company dedicated to
the research, development and commercialization of innovative
therapies for rare and severe diseases of the eye. Kala’s
biologics-based investigational therapies utilize Kala’s
proprietary mesenchymal stem cell secretome (MSC-S) platform.
Kala’s lead product candidate, KPI-012, is a human MSC-S, which
contains numerous human-derived biofactors, such as growth factors,
protease inhibitors, matrix proteins and neurotrophic factors that
can potentially correct the impaired corneal healing that is an
underlying etiology of multiple severe ocular diseases. KPI-012 is
currently in clinical development for the treatment of persistent
corneal epithelial defect (PCED), a rare disease of impaired
corneal healing, for which it has received Orphan Drug and Fast
Track designations from the U.S. Food and Drug Administration. Kala
is also targeting the potential development of KPI-012 for the
treatment of Limbal Stem Cell Deficiency and other rare corneal
diseases that threaten vision and has initiated preclinical studies
to evaluate the potential utility of its MSC-S platform for retinal
degenerative diseases, such as Retinitis Pigmentosa and Stargardt
Disease. For more information on Kala, please visit
www.kalarx.com.
Investor Contact:
Hannah Deresiewiczhannah.deresiewicz@sternir.com212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Apr 2024 to May 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2023 to May 2024